Being overweight almost doubles risk of womb cancer

Written By :  Dr. Kamal Kant Kohli
Published On 2022-04-22 00:45 GMT   |   Update On 2022-04-22 09:09 GMT

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer*, according to a Cancer Research UK-funded study published today in BMC Medicine**.The study from the University of Bristol is one of the first to find that for every 5 extra BMI units, a woman's risk of endometrial cancer is almost doubled (increase of 88%). This is higher than most...

Login or Register to read the full article

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer*, according to a Cancer Research UK-funded study published today in BMC Medicine**.

The study from the University of Bristol is one of the first to find that for every 5 extra BMI units, a woman's risk of endometrial cancer is almost doubled (increase of 88%). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. 5 BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier.

The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

The researchers looked at markers of 14 traits, which could link obesity and womb cancer. They uncovered two hormones - fasting insulin and testosterone – which increased the risk of being diagnosed with womb cancer. By pinpointing exactly how obesity increases the risk of cancer, such as through hormones, scientists in the future could use drugs to reduce or increase the level of these hormones in people already at a higher risk of cancer. For example, drugs like metformin used in diabetes treatment can reduce the levels of hormones and research suggests this drug also affects cancer risk, though further study is ongoing.

Womb cancer is one of the cancer types most closely linked with obesity. It's the most common gynecological cancer in high income countries and is the fourth most common cancer for women in the UK – 1 in 36 women will be diagnosed in their lifetime. And of UK womb cancer cases, it's estimated that around a third are caused by being overweight and obese.

Being overweight or obese is the second highest preventable cause of cancer in the UK. It's estimated that more than one in 20 cancer cases in the UK are caused by excess weight.

Emma Hazelwood, lead author of the paper said: "This study is an interesting first step into how genetic analyses could be used to uncover exactly how obesity causes cancer, and what can be done to tackle it. Links between obesity and womb cancer are well-known but this is one of the largest studies which has looked into exactly why that is on a molecular level. We look forward to further research exploring how we can now use this information to help reduce the risk of cancer in people struggling with obesity."

Dr Julie Sharp, head of health information at Cancer Research UK said: "Cancer Research UK has been leading the way in uncovering links between obesity and cancer for years. Studies like this bolster the fact that being overweight or obese is the second biggest cause of cancer in the UK and can help us start to pinpoint why. This will play a pivotal role in uncovering how to prevent and treat cancer in the future.

"More research is needed to investigate exactly which treatments and drugs could be used to manage cancer risk among people struggling with obesity. We already know that being overweight or obese increases your risk of developing 13 different types of cancer. To reduce your cancer risk, it's important to maintain a healthy weight by eating a balanced diet and staying active."

Tags:    
Article Source : BMC Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News